Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody...
5 insider purchases on record · latest filing 2024-03-15.
Insiders have also filed 60 sale transactions at SKYE.